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INTRODUCTION
Approximately 350 million individuals world-wide are car-
riers of hepatitis B virus (HBV) [1]. Chronic HBV infection is
the cause of up to 50% of cirrhosis and 70±90% of cases of
hepatocellular carcinoma (HCC) in China, South-east Asia
and Africa [2,3]. It is estimated that during 1990, 229 000
HCC cases world-wide were attributable to HBV infection [4].
Among the 350 million HBV carriers, 7±30% are believed
to be infected with HBV variants that express little or no
hepatitis B e antigen (HBeAg) [5]. The typical course of
hepatitis B infection involves an HBeAg-positive phase with
high serum HBV DNA levels. Subsequently, patients undergo
a process of seroconversion in which HBeAg is lost and
antibodies to HBeAg (anti-HBe) appear. Generally this sig-
nals the decline of HBV DNA to levels that are not detectable
by unampli®ed assays and a return of aminotransferase to
normal values. Among some patients, for reasons that are
not yet clear, the immune pressure associated with sero-
conversion selects for HBV variants that express little or no
HBeAg. Although the patient may develop anti-HBe, active
HBV DNA replication continues with associated liver dam-
age [5].
There are a variety of mutations in the core promoter and
pre-core region that can decrease or prevent the synthesis of
HBeAg without adversely affecting the ability of the HBV to
replicate. The clinical syndrome in which patients are hepa-
titis B surface antigen (HBsAg) positive for at least 6 months,
HBeAg-negative, anti-HBe positive, with HBV DNA detectable
in serum using unampli®ed assays, and active liver disease
manifested by elevated aminotransferase (AST or ALT), liver
histology showing chronic hepatitis with or without
cirrhosis or clinical evidence of cirrhosis; will be referred to as
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SUMMARY. Hepatitis B is a serious disease that is endemic in
many parts of the world. A signi®cant proportion of patients
with chronic hepatitis B (CHB) are infected with a variant
form of the hepatitis B virus (HBV) which decreases or
abolishes the production of hepatitis B e-antigen (HBeAg).
The purpose of this literature review is to describe the epi-
demiology of HBeAg-negative CHB (e-CHB) worldwide. A
literature search was conducted to identify studies pertaining
to e-CHB and underlying variants (precore and core pro-
moter). Fifty studies were included in our analysis. The
median prevalence of e-CHB among patients with chronic
HBV infection was 33% in the Mediterranean, 15% in Asia
Paci®c, and 14% in the USA and Northern Europe. The pre
core stop codon variant was detected in a median of 60%
(range 0±100%) of HBeAg-negative patients overall, 92% in
the Mediterranean, 50% in Asia Paci®c and 24% in the USA
and Northern Europe. There were very few data on the
prevalence of core promoter variants outside Asia where the
median prevalence among HBeAg-negative patients was
77%. This literature review revealed that e-CHB is more
common than previously suspected and that it is present
worldwide with marked variations in the prevalence of
associated HBV variants across different geographical
regions. Additional research using population based samples
of adequate size based on a consensus de®nition of e-CHB
and using standardized HBV DNA assays is needed to better
estimate the true prevalence of e-CHB and its associated HBV
variants.
Keywords: chronic hepatitis B, core promoter, epidemiology,
precore.
HBeAg-negative chronic hepatitis B (e-CHB) [6]. The most
commonly studied mutation associated with e-CHB is in the
pre-core region at nucleotide (nt) 1896 where adenine (A) is
substituted for guanine (G), producing a stop codon that
prematurely terminates synthesis of the HBeAg [7,8]. The
core promoter region regulates transcription of the pre-core
region. Therefore certain mutations in this region can affect
HBeAg synthesis. Speci®cally, a double mutation involving
substitution of T for A at nt 1762 and A for G at nt 1764 can
reduce pre-core mRNA and HBeAg production [9±11].
The primary aim of this literature review is to describe the
epidemiology of e-CHB and the relative prevalence of the
associated precore and core promoter variants.
METHODS
Data sources
The following terms were used to search Medline (1966 ±
April 2000) and PubMed (1966 ± April 2000): `precore' OR
`pre-core' OR `pre-C' OR `core promoter' AND `hepatitis B'.
Articles identi®ed by searches of Medline and PubMed
were evaluated according to the following inclusion criteria:
Sample size: N > 40, except in instances where the only
data available for a given country is from studies of fewer
than 40 subjects.
Evidence of chronic infection: Subjects were HBsAg-pos-
itive for at least 6 months.
Methodology:
· Adequate detail in the description of the study population
to determine the country from which the sample was
drawn.
· For clinical trials, pretreatment data on the presence of
e-CHB and HBV variants were reported.
· Determinations of HBV serology, liver disease (ALT, liver
histology or clinical presentations) and HBV DNA were
required to assess the prevalence of e-CHB.
The reference list for each article was reviewed to identify
additional publications that were not identi®ed via Medline
or PubMed.
De®nitions
HBsAg-positive (or chronic HBV infection)
Patients who were HBsAg-positive for at least six months fall
into this category, no determination was made on clinical
disease process. This term was used as a denominator to
re¯ect the proportion with e-CHB among patients with
chronic HBV infection (or HBsAg-positive).
HBeAg-negative
All patients who were HBsAg-positive but HBeAg-negative
fall into this category, without determining clinical disease
process. This term was used as a denominator to re¯ect the
proportion with e-CHB among all the patients with chronic
HBV infection (HBsAg-positive), who were HBeAg-negative.
Some studies reported only the anti-HBe status of patients.
Anti-HBe-positive patients were assumed to be HBeAg-neg-
ative for the purposes of our evaluation.
e-CHB (or HBeAg-negative chronic hepatitis B)
Patients with e-CHB were identi®ed based on the serological
and clinical information presented in each study reviewed.
Patients with e-CHB were HBsAg-positive for at least
6 months, HBeAg-negative, anti-HBe-positive, with HBV
DNA detectable in serum using unampli®ed assays, and
active liver disease (elevated AST or ALT, liver histology
showing chronic hepatitis with or without cirrhosis, or
clinical evidence of cirrhosis).
Prevalence estimates
The methods used to assess prevalence of e-CHB in each of
the studies reviewed are described in the Results section.
Because the sensitivity of assays used to detect HBV DNA will
affect prevalence estimates, the assay used in each study is
described in the table footnotes. Prevalence estimates were
not adjusted for differences in age or gender distribution,
proportion of patients who were HBeAg-positive, or pro-
portion with active or advanced liver disease. The estimates
of pre-core and core promoter variant prevalence include all
HBeAg-negative patients with or without active liver disease.
The median prevalence of e-CHB among HBeAg-negative
patients may be lower than the median prevalence of e-CHB
among HBsAg-positive patients due to the fact that different
studies contribute to the calculation of each median.
RESULTS
Two hundred and eighty-one research articles potentially
related to e-CHB were identi®ed by the literature search;
50 of these articles were included in our analysis. Two
hundred and thirty-one were rejected primarily due to in-
adequate sample size, the use of a study population that was
not generalizable (such as patients with liver transplants or
hepatocellular carcinoma), or a patient selection process that
focused on acute or fulminant hepatitis rather than chronic
hepatitis.
Asia Paci®c
The results from 26 studies conducted in the Asia Paci®c
region which include 6161 patients are summarized in
Table 1. The data from two studies (one from Taiwan,
another from Korea) included only hospitalized patients.
The remainder of the data came from clinic populations
(15 studies) or from an unknown but presumably clinic
setting (8 studies). The mean age of the study populations
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ranged from 28 to 43 years with a mean of 35.5 years.
Of the 18 studies that reported on the gender composition of
the patient population, the percentage of females ranged
from 3 to 46 with a mean of 27%.
The median prevalence of e-CHB among HBsAg-positive
patients was 15% (range: 5±47) (Table 1). The median
prevalence of e-CHB among HBeAg-negative patients was
36% (range: 9±69). The median prevalence of pre-core

















[19] 227 nr 37(e)) 55k 8 18 nr nr
[42] 61 84c 25(a+) nr nr nr 100 nr
[43] 273 62d 58(e)) 77j 31 54 42 nr
47(a+)
[44] 55 56d 45(e)) nr 24f 52 52 nr
[20] 93 51c 49(e)) nr 17 35 100 98
[21] 42 74 40g 90 71
[22] 169 100 49(e)) nr nr nr nr 87
[45] 103 76c 55(a+) nr nr nr 23 79
[10] 113 nr 53(e)) nr nr nr 43 77
Mainland China
[46] 54 100 nr nr nr nr 63 nr
[47] 77 nr 100(e), a+) 66j nr 66a 48 nr
[48] 446 nr 45(a+) 53j 16a 35a 19 nr
[49] 177 50c 53(e)) 84j 26b 49b 57 59
Hong Kong
[23] 308 49 35(e)) 85j 10c 29c 22 nr
[6] 350 45 69(e)) 39m 12d 17d 37 65
Taiwan
[50] 79 42d 32(e)) 86k 15d/k 48d/k nr nr
[51] 94 100c 100(a+) 36k nr 36g nr nr
[52] 2582 38 56(e)) nr 12e 21e nr nr
[53] 62 53d 44(e)) nr 21h 48h 93 nr
Korea
[54] 66 nr 48(e)) nr nr nr 80 nr
[55] 57 91d 56(e)) 96j nr nr 50 nr
India
[56] 72 100 54(e)) 61k 15 28 nr nr
[57] 120 nr nr nr 15 nr nr nr
Singapore
[58] 404 nr 56(e)) 42k 5f 9f nr nr
Thailand
[59] 34 74d 68(e)) 65j 47i 69i nr nr
Malaysia
[60] 43 28c 33(e)) 100j nr nr 21 nr
nr, not reported; e), % HBeAg-negative; a+, % anti-HBe-positive; PreC, precore variant; CP, core promoter variant;
u, unknown. aHBV DNA+ and HBsAg+ > 6 month. bElevated ALT and liver histology showing hepatitis with or without
cirrhosis. cElevated ALT. dChronic active hepatitis with or without cirrhosis. eHBeAg), ALT > 1.5 times ULN, DNA+.
fALT > 1.5x ULN, HBV DNA+. gAnti-HBe+, ALT > 2 times ULN (both inclusion criteria), HBV DNA+ by spot hybridization.
hHBeAg) and diagnosis of chronic active hepatitis. iHBeAg)and ALT > ULN. jPCR ampli®ed DNA; kHybridization assay;
l> 105 copies/mL; mBranched DNA assay.
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variants among HBeAg-negative patients was 50% (range:
19±100) and the median prevalence of core promoter
variants among HBeAg-negative patients was 77% (range:
59±98).
Mediterranean
The results from 17 studies conducted in the Mediterranean
which include 1374 patients are summarized in Table 2.
The data from two studies (both from Israel) were derived
from samples analysed by diagnostic laboratories. The
remainder of the data came from clinic populations (10
studies) or from an unknown but presumably clinic setting
(5 studies). The mean age of the study populations ranged
from 32 to 54 years with a mean of 40.8 years. Of the 12
studies that reported on the gender composition of the
patient population, the percentage of females ranged from
13 to 33 with a mean of 25%.
The median prevalence of e-CHB among HBsAg-
positive patients was 33% (range: 10±72) (Table 2).
The median prevalence of e-CHB among HBeAg-negative
patients was 24% (range: 0±84). The median prevalence
of precore variants among HBeAg-negative patients was 92%
(range: 67±100) and the single study from Turkey of core
promoter variants reported a prevalence of 0%.
USA/Northern Europe
The results from seven studies conducted in the United States
and Northern Europe that include 712 patients are sum-
marized in Table 3. The data from two studies (both Ger-
man) were derived from samples analysed by diagnostic
laboratories and one French study reported on hospitalized
patients. The rest of these studies evaluated patients from
clinic settings. The mean age of the study populations ran-
ged from 38 to 51 years with a mean of 41.5 years. Of the

















[61] 116 71d 54(e)) nr 38f 70f nr nr
[62] 106 28d 100(a+) 26b nr 17 nr nr
[63] 92 64d 30(e), a+) 80b 10 32 nr nr
[64] 118 22d 100(a+) 24b nr 19 nr nr
[65] 42 60d 100(a+) 100a nr nr 88 nr
[66] 106 100c/71d 60(a+) 100a nr nr 95 nr
[27] 115 100c/71d 50(a+) 100a nr nr 97 nr
[67] 41 85c 71(a +) 100a nr nr 86 nr
Greece
[68] 33 68d 76(e)) 64b 33 44 nr nr
[69] 36 86f 86(e)) 86b 72e 84e 100 nr
Spain
[70] 99 80c/81d 63(a+) 47b 15b/c 24b/c nr nr
[71] 45 100c 100(a+) 0b nr 0 67 nr
[25] 42 88c/71d 55(a+) 69b nr nr 96 nr
Israel
[72] 153 nr 100(e)) 7b nr 7 nr nr
[73] 120 nr 100(e)) 8b nr 8 100 nr
Bulgaria
[74] 29 69d 100(a+) 38g nr 34d/g 89 nr
Turkey
[75] 81 nr 42(e)) 100a nr nr 85 0
nr, not reported; e), % HBeAg-negative; a+, % anti-HBe positive; PreC, precore variant; CP, core promoter variant.
aPCR ampli®ed DNA. bHybridization assay. cElevated ALT. dChronic active hepatitis with or without cirrhosis. eHBeAg),
ALT > 1.5 times ULN, HBV DNA+. fALT > 1.5 ULN, HBV DNA+. g  50 pg/200 mL.
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®ve studies that reported on the gender composition of the
patient population, the percentage female ranged from seven
to 26 with a mean of 18.2%.
The median prevalence of e-CHB among HBsAg-positive
patients was 14% (range: 13±22) (Table 3). The median
prevalence of e-CHB among HBeAg-negative patients was
22% (range: 15±30). The median prevalence of precore
variants among HBeAg-negative patients was 24% (range:
0±53) and the single study from Germany of core pro-
moter variants reported a prevalence of 59%.
Global prevalence of e-CHB, precore
and core promoter variants
The bubble graph shown in Fig. 1 provides a synthesis of
the prevalence data for e-CHB, precore and core promoter

















[76] 33 58c 100(e), a+) 30i nr 30 24 nr
[77]* 45 64d 9(e)) 89g nr nr 0 nr
Germany
[33] 96 100a 33(e)) 100g nr nr 53 59
[78] 127 nr 100(a+) 54f nr nr 16 nr
[79] 93 nr 84(e), a+) 27h 13e 15e 40 nr
France
[80] 276 100b 22(e), a+) 100g 22 nr nr nr
Sweden
[81] 42 40c 67(e)) 65f 14 22 nr nr
nr, not reported; e), % HBeAg-negative; a+, % anti-HBe positive; PreC, precore variant; CP, core promoter variant;
u, unknown. *Included patients from the USA and UK. aDNA+ and HBsAg+ > 6 month. bElevated ALT and liver histology
showing hepatitis with or without cirrhosis. cElevated ALT. dChronic active hepatitis with or without cirrhosis. eHBV
DNA+ (> 105 copies/mL). fPCR ampli®ed DNA. gHybridization assay. h> 105 copies/mL. iBranched DNA assay.
Fig. 1 Estimates of the prevalence of
e-CHB, precore and core promoter
variants among HBsAg-positive/HBeAg-
negative subjects grouped by region.
 Bubble size is proportionate to the
sample size of the study population.
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variants among HBsAg-positive, HBeAg-negative subjects
grouped by region. The size of each bubble is proportionate
to the size of the study population.
DISCUSSION
Noncomparability due to differences in de®nitions
and measurement
In addition to demographic differences in study populations
described above that would be expected to in¯uence the
prevalence of e-CHB, there are two major sources of vari-
ability in the data collected that may contribute to non-
comparability between estimates even if the underlying
prevalence was the same. The lack of a standardized de®ni-
tion of e-CHB, or chronic hepatitis for that matter, makes it
very dif®cult to compare the results across studies. Some
studies de®ned e-CHB based on elevated ALT alone, others
based their ®ndings on DNA tests, and yet others utilize a
combination of biochemical, histological and/or clinical
assessment. This highlights the need for a consensus de®-
nition of e-CHB [12].
The second major source of variability is the lack of
standardized HBV DNA assays and increased sensitivity of
HBV DNA assays over time. As a result, a patient previously
considered to have undetectable serum HBV DNA using
hybridization assays with sensitivity limits of approximately
1 million copies/mL would now be considered to have
ongoing HBV replication based on the results of polymerase
chain reaction (PCR) assays which can detect a few hundred
copies/mL of HBV DNA. In order that results from different
studies can be compared, the type of assays used to detect
serum HBV DNA, and their sensitivity and range of linearity
must be reported. In addition, all HBV DNA assays should be
standardized against a panel of international standards.
Another hurdle in the understanding of the literature on
e-CHB is that some researchers equate the clinical syndrome
of e-CHB with the presence of the precore stop codon
mutation (G1896A) despite the fact that the predominant HBV
strain in these patients may be: (i) wild type in the pre-core
and core promoter regions; (ii) precore stop codon variant;
(iii) dual core promoter variant; (iv) combination of precore
stop codon and core promoter variant; or (v) variants with
other nonsense mutations in the precore region. Future
research needs to report phenotypic as well as genotypic data
to determine if the clinical outcome and response to treat-
ment of patients with e-CHB correlate with the predominant
sequence in the precore and core promoter regions.
e-CHB prevalence
The results from this literature review suggest that e-CHB is
more common than previously suspected, that it can be
found world-wide, and that it is not invariably associated
with precore mutation (Fig. 1). The median prevalence of
e-CHB among HBsAg-positive patients was 33% in the
Mediterranean, 15% in Asia Paci®c, and 14% in the United
States and Northern Europe. Although e-CHB is more
common in the Mediterranean, the impact is greatest in
China where a prevalence of 15% among HBsAg carriers
translates into approximately 15 million cases of e-CHB.
The median prevalence of e-CHB among HBsAg-positive/
HBeAg-negative patients was 32%, with the highest median
prevalence in Asia Paci®c (36%) and lower prevalences in
the Mediterranean (24%) and the United States and
Northern Europe (22%). The differences in prevalence of
e-CHB in different regions of the world are in part related to
the variability in study design and sample selection, but an
important explanation is the geographical variation in HBV
genotypes [13±16].
Experience of clinical investigators in many parts of the
world suggests that the prevalence of e-CHB is increasing
over time [17,18]. This clinical impression is supported by
data from a few studies. A study conducted in Japan between
1981 and 1984 found that 8% of HBsAg-positive patients
met the de®nition of e-CHB [19]. A decade later, three studies
show that the percentage has at least doubled [20±22].
Preliminary data from Italy also indicate that e-CHB is on the
rise. Nevertheless, de®nitive evidence in support of an in-
crease in prevalence of e-CHB in the last decade is lacking
because of the scarcity of population-based studies.
Our ®ndings contradict the conventional wisdom that
e-CHB is not common outside of the Mediterranean. The
belief that e-CHB is a Mediterranean problem may stem from
the fact that research on this phenomenon originated in that
part of the world. At the same time, these data indicate that
e-CHB is not as common in the Mediterranean as recent
anecdotal reports of e-CHB rates of 80% among HBsAg
carriers in Italy would suggest. The lower rates reported here
may re¯ect differences in the sensitivity of the assays used to
detect HBV DNA or in the proportion of the study popula-
tions with active disease. It is also possible that there is a
genuine increase in prevalence of e-CHB during the last
15 years that is not re¯ected in the published literature.
HBeAg-negative variants
The pre-core mutation (G1896A) can be detected in 20±95%
of HBeAg-negative patients in most areas, but the preval-
ence is highest in the Mediterranean countries (> 85%).
Geographic variation in the prevalence of the precore
variant is related to the fact that the occurrence of the
G1896A mutation is restricted to HBV genotypes with T at
nucleotide position 1858. Thus, the G1896A precore variant
is most prevalent in HBV genotype D, the predominant
genotype in the Mediterranean countries, intermediate in
genotypes B and C, the most frequent genotypes in Japan
and Southeast Asia, and rare in genotype A, the most
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common genotype in North America and Northern Europe
[14,23±25].
Unlike the precore mutation, the core promoter muta-
tions A1762T and G1764A can be found in HBV genotypes
with C at nucleotide 1858. In fact, there is some evidence
that the core promoter mutations are more likely to be
selected in genotypes with a C rather than T at 1858 [26].
These ®ndings suggest that the geographical distribution of
core promoter and pre-core variants may be different, and
e-CHB may not be limited to the Mediterranean and Asia
(Fig. 1). Our study showed that e-CHB has been reported
worldwide and core promoter variants are common in Asia
Paci®c but very little data about the prevalence of core
promoter variants in other regions of the world are available.
Population-based evidence
Nearly all of the studies reviewed were conducted in hospital-
based clinic populations which we would not expect to be
representative of all HBsAg carriers. In addition, disease
severity varied across the study populations. Moreover, very
few were cross-sectional studies that enrolled consecutive
patients. Rather, most studies were retrospective and likely to
be biased towards patients with more severe liver disease.
Thus, our prevalence estimates based on review of existing
literature have major limitations.
Apart from the geographical location and predominant
HBV genotype, various factors may affect the prevalence of
e-CHB including gender, age, treatment history, and duration
of infection. Because all of these factors vary between studies,
comparing the results of one study with another or combi-
ning the results of several studies from the same region may
not be appropriate. In order to better understand the complex
interplay between these factors and the development of
e-CHB, suf®ciently large studies using multivariate tech-
niques to adjust for these potential confounders are needed.
Clinical implications
Several studies found that treatment of e-CHB with inter-
feron is more dif®cult because of a high rate of relapse after
treatment is stopped [27±30]. The exact reason for the low
rate of sustained response is not clear. Studies that examined
the correlation between precore and core promoter variants
and response to interferon treatment have yielded con¯icting
results [27,29,31]. One study found that e-CHB patients
with precore stop codon variant comprising > 20% of the
viral population were less likely to have a sustained response
to interferon treatment [27]. However, another study of
HBeAg-positive Chinese patients treated with interferon
found that those with the precore stop codon mutation were
more likely to clear HBeAg and to do so earlier [32]. A recent
study by Erhardt et al. [33] reported that among HBeAg-
negative patients, core promoter mutations were associated
with higher HBV DNA levels and poorer sustained response
to interferon but the converse was true for HBeAg-positive
patients. In that study, precore mutation had no correlation
with response to treatment.
Clinical trials showed that lamivudine induces effective
suppression of HBV replication leading to normalization of
aminotransferases and signi®cant improvements in histo-
logy, indicating that the responses among e-CHB patients are
similar to those seen in studies of HBeAg-positive chronic
hepatitis B patients [34±40]. However, most patients relapse
after treatment is stopped [37]. Research continues to
determine response rates to longer courses of lamivudine
treatment and the durability of response post treatment. One
study suggested that patients with core promoter variants
are more likely to develop breakthrough infection [41], but
additional studies are needed to determine if there is a cor-
relation between response to lamivudine and core promoter
or pre-core mutations.
CONCLUSIONS
Our literature review showed that e-CHB is present in Asia,
the United States, Northern Europe and the Mediterranean
and may be increasing. There are variations in the prevalence
of e-CHB and the prevalence of precore and core promoter
variants among HBeAg-negative patients in different parts of
the world. However, absence of population-based studies,
lack of standardized de®nition of e-CHB and variations in HBV
DNA assays preclude de®nitive conclusion on the true pre-
valence of e-CHB and the contribution of precore and core
promoter variants to e-CHB in each geographical region.
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